FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication Compounded "semaglutide" is not FDA approved semaglutide.com Important Update on FDA Changes Concerning Peptides FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News